DOCSLIB.ORG

Compositions and Methods for Treating Contracture

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Compositions and Methods for Treating Contracture (19) & (11) EP 1 708 694 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/335 (2006.01) 11.07.2012 Bulletin 2012/28 (86) International application number: (21) Application number: 05722794.4 PCT/US2005/003800 (22) Date of filing: 31.01.2005 (87) International publication number: WO 2005/074913 (18.08.2005 Gazette 2005/33) (54) COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON KONTRAKTUR COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DE LA CONTRACTURE (84) Designated Contracting States: • LOSS, Troy, A., E. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR North Vancouver, British Columbia V7L 3G (CA) HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR • GRAVETT, David, M. Vancouver, British Columbia V5Z 1Y8 (CA) (30) Priority: 30.01.2004 US 540660 P • MAITI, Arpita Vancouver, British Columbia V5Z 4A6 (CA) (43) Date of publication of application: 11.10.2006 Bulletin 2006/41 (74) Representative: Gowshall, Jonathan Vallance et al Forresters (73) Proprietor: ANGIOTECH INTERNATIONAL AG Skygarden 6304 Zug (CH) Erika-Mann-Strasse 11 80636 München (DE) (72) Inventors: • AVELAR, Rui (56) References cited: Vancouver, British Columbia V6J 2W7 (CA) EP-A- 1 508 331 WO-A-98/24427 • LIGGINS, Richard, T. WO-A-98/24427 US-A1- 2002 183 380 Coquitlam, British Columbia V3K 5K7 (CA) US-A1- 2002 183 380 US-A1- 2004 001 872 • TOLEIKIS, Philip, M. Vancouver, British Columbia V6P 5N8 (CA) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 708 694 B1 Printed by Jouve, 75001 PARIS (FR) EP 1 708 694 B1 Description Technical Field 5 [0001] The present invention relates generally to pharmaceutical compositions and methods for preventing conditions associated with reduced mobility or loss of function and articulation. Background of the Invention 10 [0002] The normal function of a joint and its movement can be severely impaired by scar and abnormal tissue formation that takes place both inside and outside the joint. The result is reduced mobility of a joint or extra- articular structure such as a muscle, tendon, or ligament. Reduced mobility can involve permanently shortened distances between tissues or a reduced maximum possible lengthening or shortening of tissues. When the impaired mobility results from one of these conditions, it is generally referred to as a contracture. The term "contracture" is often used interchangeably with the 15 terms such as "stiff joint" or arthrofibrosis. [0003] Contractures can be associated with or caused by a variety of conditions, for example, metabolic disorders, ischemia, burns, injury (e.g., to joint, capsule, bone, cartilage, tendon, ligament or muscle), fractures, subluxation, dis- locations, crush injuries, prolonged immobilization ( e.g., immobilization of a joint in a cast or splint), and paralysis. Surgical procedures may also precipitate contractures, as in the case of operations involving the shoulder ( e.g., rotator cuff repair 20 or diagnostic inspection), elbow, and hand. Other procedures involving joint reduction after a dislocation, or repairs of tendon, ligament, capsule and bone may also induce joint contractures. Procedures to remove scar and abnormal tissue in contracted joints often fail because the surgery itself represents a controlled injury. Thus, the process of removing abnormal and scarred tissue further stimulates the formation of scarred and abnormal tissue. As a result, the procedures offered today have limited success and at times, can actually make a patient worse. 25 [0004] Certain joints and procedures have higher tendencies for contractures. For example, a hip or knee arthroplasty generally has a low rate of joint stiffness after a procedure, but a shoulder has a significantly higher rate. An anterior cruciate repair has an incidence of arthrofibrosis ranging from 3% to 15% depending on the surgeon and repair performed (e.g., semi-tendinous/gracilis or bone-patellar tendon bone repair). Joints such as the elbow have a high tendency and can form some degree of contracture in 30% to 70% of patients. Shoulders may form contractures not only in response 30 to trauma, but can also form spontaneously, for example, a frozen shoulder with a capsule that has thickened without any obvious precipitant. [0005] In certain cases, the contracture may have a hereditary basis and have the primary scar and abnormal tissue growth take place outside of the joint. Dupytren’s contracture represents a condition whereby the connective tissue in the palmer aspect of the hand begins to scar and thicken leading to deformation of the hand at the site of the thickening 35 and loss of range of motion of the fingers. Equivalent scenarios exist in the penis (Peyronie’s disease), and on the plantar aspect of the foot (Ledderhose’s disease). [0006] Treatment for contractures today only addresses the issue after a contracture is already established. Interven- tions including only physiotherapy and range of motion exercises are used but have very limited success. Surgical interventions include manipulation under anesthesia ( i.e., essentially putting the patient to sleep and then breaking down 40 the adhesion by forcing the joint). Unfortunately, this often reignites the inflammation and proliferation in the tissue and the reformation of the scar and stiffness. Surgery may involve an open procedure, releasing and removing the restricting scar and abnormal tissue or the operation can also be done through an arthroscope, whereby the scar and restricting tissue is released and removed using special tools. Surgical interventions often fail, and may actually make the condition worse, since the surgery itself is a controlled injury or trauma, which can cause the tissue to lay down even more scar 45 in response to the surgical injury. [0007] Pharmacological therapy has been attempted with limited or no success. Agents most often used include non- steriodal anti-inflammatories, steroids and radiation. Pharmacological treatments for various types of contracture have included administration of hyaluronic acid ( i.e., HEALON-R, Pharmacia Inc., Piscataway, NJ) into joints (Clin. Rheumatol. 20: 98-103, 2001; Acta Orthop. Scand. 62: 323-6, 1991); oral administration of antihistamines to rabbits (J. Hand Surg. 50 18: 1080-5, 1993); and intra-articular injection of dimethlysulfoxide, systemic steroids, and non- steroidal anti-inflamma- tories. Recombinant human superoxide dismutase (U.S. 6,312,720), calmodulin blockertrifluroperizine (U.S. 6,525,100), collagenase and calcium channel blockers have been disclosed as therapy for patients suffering from Peyronie’s disease; matrix metalloproteinase inhibitors have been disclosed for inhibiting contraction (see, e.g., U.S. Patent No. 6,093,398); and use of dimethylsulfoxide, oxygen free radical scavengers, including colchicine, allopurinol, and methylhydrazine, 55 interferon, collagenases, steroids, such as triamcinolone and clobetasol(Hand Clinics 15: 97-107, 1999), verapamil, nifedipine, diltiazem, amalodipine, felodipine, isradipine, nicardipine, nimodipine, nisoldipine, bepridil (see,e.g ., U.S. Patent Nos. 6,353,028 and 6,031,005) and fluroquinolone (U.S. Patent No. 6,060,474) have been injected locally into fibrous tissue in an attempt to treat Dupuytren’s contracture. To date, however, none of the pharmacological treatments 2 EP 1 708 694 B1 described above have been approved for treating contracture in human patients. SUMMARY OF THE INVENTION 5 [0008] The present invention provides the claimed compositions, for use in devices and methods for the treatment of contracture, and in particular, for use in human and animal patients. The compositions described herein may be used after an injury in order to prevent or minimize contracture formation. In the case of established contracture, the compo- sitions of the invention can be used to complement a release proceduree.g (., forced manipulation, open release, arthroscopic release, or debulking of scar) to prevent the recurrence of scarred and abnormal tissue which can lead to 10 a contracture. The administration may be intra-articular in cases where the contracture is caused by an intra-articular scar, or may used peri-articularly where the contracture is caused by not only scarring within the joints, but also by scar tissue outside the joint. An example of the latter would include interphalangeal contractures, not only is the scar within the joint, the outside volar plate is also involved. The use or administration of the instant compositions provides for an efficacious treatment which is reasonably safe and well tolerated and may further provide other related advantages. The 15 drug contained in the compositions of the invention may be selected from a variety of therapeutically active compounds which will provide symptomatic, disease modifying or prophylaxis effect in conditions associated with contracture. The method of use of such compositions may also vary, but includes all routes of administration, doses, and dosing frequencies which will provide such a benefit. [0009] In one aspect, a method for treating contracture is provided that includes administering to a patient
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0070488A1 Coelingh Bennik Et Al
    US 2005.0070488A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0070488A1 Coelingh Bennik et al. (43) Pub. Date: Mar. 31, 2005 (54) ESTROGENIC COMPOUNDS IN prises the oral administration of an estrogenic component COMBINATION WITH PROGESTOGENIC and a progestogenic component to a mammal in an effective COMPOUNDS IN amount to prevent or treat Symptoms of hypoestrogenism, HORMONE-REPLACEMENT THERAPY wherein the estrogenic component is Selected from the group (76) Inventors: Herman Jan Tijmen Coelingh Bennik, consisting of Substances represented by the above formula in Driebergen (NL); Evert Johannes which formula R, R2, R, R independently are a hydrogen Bunschoten, Heesch (NL); Christian atom, a hydroxyl group or an alkoxy group with 1-5 carbon Franz Holinka, New York, NY (US) atoms; each of Rs, R, R-7 is a hydroxyl group; and no more than 3 of R, R2, R, R are hydrogen atoms; precursors Correspondence Address: capable of liberating a Substance according to the aforemen William Logsdon tioned formula when used in the present method; and Webb Ziesenheim Logsdon Orkin & Hanson mixtures of one or more of the aforementioned Substances 700 Koppers Building and/or precursors. Another aspect of the invention concerns 436 Seventh Avenue a pharmaceutical kit comprising oral dosage units that Pittsburgh, PA 15219-1818 (US) contain the aforementioned estrogenic component and a (21) Appl. No.: 10/495,707 progestogenic component as well as an androgenic compo nent. (22) PCT Filed: May 23, 2002 (86) PCT No.: PCT/NL02/00332 (30) Foreign Application Priority Data Nov. 15, 2001 (EP)........................................ O1204377.4 Feb.
    [Show full text]
  • Chemical Composition and Product Quality Control of Turmeric
    Stephen F. Austin State University SFA ScholarWorks Faculty Publications Agriculture 2011 Chemical composition and product quality control of turmeric (Curcuma longa L.) Shiyou Li Stephen F Austin State University, Arthur Temple College of Forestry and Agriculture, [email protected] Wei Yuan Stephen F Austin State University, Arthur Temple College of Forestry and Agriculture, [email protected] Guangrui Deng Ping Wang Stephen F Austin State University, Arthur Temple College of Forestry and Agriculture, [email protected] Peiying Yang See next page for additional authors Follow this and additional works at: http://scholarworks.sfasu.edu/agriculture_facultypubs Part of the Natural Products Chemistry and Pharmacognosy Commons, and the Pharmaceutical Preparations Commons Tell us how this article helped you. Recommended Citation Li, Shiyou; Yuan, Wei; Deng, Guangrui; Wang, Ping; Yang, Peiying; and Aggarwal, Bharat, "Chemical composition and product quality control of turmeric (Curcuma longa L.)" (2011). Faculty Publications. Paper 1. http://scholarworks.sfasu.edu/agriculture_facultypubs/1 This Article is brought to you for free and open access by the Agriculture at SFA ScholarWorks. It has been accepted for inclusion in Faculty Publications by an authorized administrator of SFA ScholarWorks. For more information, please contact [email protected]. Authors Shiyou Li, Wei Yuan, Guangrui Deng, Ping Wang, Peiying Yang, and Bharat Aggarwal This article is available at SFA ScholarWorks: http://scholarworks.sfasu.edu/agriculture_facultypubs/1 28 Pharmaceutical Crops, 2011, 2, 28-54 Open Access Chemical Composition and Product Quality Control of Turmeric (Curcuma longa L.) ,1 1 1 1 2 3 Shiyou Li* , Wei Yuan , Guangrui Deng , Ping Wang , Peiying Yang and Bharat B. Aggarwal 1National Center for Pharmaceutical Crops, Arthur Temple College of Forestry and Agriculture, Stephen F.
    [Show full text]
  • The Chemotherapy of Malignant Disease -Practical and Experimental Considerations
    Postgrad Med J: first published as 10.1136/pgmj.41.475.268 on 1 May 1965. Downloaded from POSTGRAD. MED. J. (1965), 41,268 THE CHEMOTHERAPY OF MALIGNANT DISEASE -PRACTICAL AND EXPERIMENTAL CONSIDERATIONS JOHN MATTHIAS, M.D., M.R.C.P., F.F.A., R.C.S. Physician, The Royal Marsden Hospital, London, S.W.3. THE TERM chemotherapy was introduced by positively charged alkyl (CH2) radicles of Ehrlich to describe the specific and effective the agent. treatment of infectious disease by chemical (a) The nitrogen mustards: mustine (HN2 substances. It is currently also applied to the 'nitrogen mustard', mechlorethamine, treatment of malignant disease. Unfortunately mustargen), trimustine (Trillekamin no aspect of tumour metabolism has been HN3), chlorambucil (Leukeran, phenyl discovered which has allowed the development butyric mustard), melphalan (Alkeran, of drugs capable of acting specifically upon the phenyl alanine mustard), uramustine malignant cell, so that cytotoxic drugs also (Uracil mustard), cyclophosphamide affect normal cells to a greater or lesser degree. (Endoxan or Cytoxan), mannomustine The most susceptible or sensitive of the normal (DegranoO). tissues are those with the highest rates of cell (b) The ethylenamines: tretamine (trie- turnover and include the haemopoietic and thanomelamine, triethylene melamine, lympho-reticular tissues, the gastro-intestinal TEM), thiotepa (triethylene thiopho- the the testis and the hair epithelium, ovary, sphoramide), triaziquone (Trenimon).by copyright. follicles. (c) The epoxides: triethyleneglycoldigly- Cancer chemotherapy may be said to encom- cidyl ether (Epodyl). pass all treatments of a chemical nature (d) The sulphonic acid esters: busulphan administered to patients with the purpose of (Myleran), mannitol myleran. restricting tumour growth or destroying tumour 2.
    [Show full text]
  • In Vitro Immunopharmacological Profiling of Ginger (Zingiber Officinale Roscoe)
    Research Collection Doctoral Thesis In vitro immunopharmacological profiling of ginger (Zingiber officinale Roscoe) Author(s): Nievergelt, Andreas Publication Date: 2011 Permanent Link: https://doi.org/10.3929/ethz-a-006717482 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library DISS. ETH Nr. 19591 In Vitro Immunopharmacological Profiling of Ginger (Zingiber officinale Roscoe) ABHANDLUNG zur Erlangung des Titels DOKTOR DER WISSENSCHAFTEN der ETH ZÜRICH vorgelegt von Andreas Nievergelt Eidg. Dipl. Apotheker, ETH Zürich geboren am 18.12.1978 von Schleitheim, SH Angenommen auf Antrag von Prof. Dr. Karl-Heinz Altmann, Referent Prof. Dr. Jürg Gertsch, Korreferent Prof. Dr. Michael Detmar, Korreferent 2011 Table of Contents Summary 6 Zusammenfassung 7 Acknowledgements 8 List of Abbreviations 9 1. Introduction 13 1.1 Ginger (Zingiber officinale) 13 1.1.1 Origin 14 1.1.2 Description 14 1.1.3 Chemical Constituents 15 1.1.4 Traditional and Modern Pharmaceutical Use of Ginger 17 1.1.5 Reported In Vitro Effects 20 1.2 Immune System and Inflammation 23 1.2.1 Innate and Adaptive Immunity 24 1.2.2 Cytokines in Inflammation 25 1.2.3 Pattern Recognition Receptors 29 1.2.4 Toll-Like Receptors 30 1.2.5 Serotonin 1A and 3 Receptors 32 1.2.6 Phospholipases A2 33 1.2.7 MAP Kinases 36 1.2.8 Fighting Inflammation, An Ongoing Task 36 1.2.9 Inflammation Assays Using Whole Blood 38 1.3 Arabinogalactan-Proteins 39 1.3.1 Origin and Biological Function of AGPs 40 1.3.2 Effects on Animals 41 1.3.3 The ‘Immunostimulation’ Theory 42 1/188 2.
    [Show full text]
  • Journal Pre-Proof
    Journal Pre-proof Steroid hormones in the aquatic environment J.O. Ojoghoro, M.D. Scrimshaw, J.P. Sumpter PII: S0048-9697(21)03377-5 DOI: https://doi.org/10.1016/j.scitotenv.2021.148306 Reference: STOTEN 148306 To appear in: Science of the Total Environment Received date: 19 April 2021 Revised date: 3 June 2021 Accepted date: 3 June 2021 Please cite this article as: J.O. Ojoghoro, M.D. Scrimshaw and J.P. Sumpter, Steroid hormones in the aquatic environment, Science of the Total Environment (2018), https://doi.org/10.1016/j.scitotenv.2021.148306 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2018 © 2021 Published by Elsevier B.V. Journal Pre-proof Steroid Hormones in the Aquatic Environment Ojoghoro, J.O.a, Scrimshaw, M.D.b* and Sumpter, J.P.b a Department of Botany, Faculty of Science, Delta State University Abraka, Delta State, Nigeria b Division of Environmental Science, Department of Life Sciences, Brunel University London, Uxbridge, Middlesex, UB8 3PH, United Kingdom Abstract Steroid hormones are extremely important natural hormones in all vertebrates.
    [Show full text]
  • Dualism of Peroxisome Proliferator-Activated Receptor Α/Γ: a Potent Clincher in Insulin Resistance
    AEGAEUM JOURNAL ISSN NO: 0776-3808 Dualism of Peroxisome Proliferator-Activated Receptor α/γ: A Potent Clincher in Insulin Resistance Mr. Ravikumar R. Thakar1 and Dr. Nilesh J. Patel1* 1Faculty of Pharmacy, Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Gujarat, India. [email protected] Abstract: Diabetes mellitus is clinical syndrome which is signalised by augmenting level of sugar in blood stream, which produced through lacking of insulin level and defective insulin activity or both. As per worldwide epidemiology data suggested that the numbers of people with T2DM living in developing countries is increasing with 80% of people with T2DM. Peroxisome proliferator-activated receptors are a family of ligand-activated transcription factors; modulate the expression of many genes. PPARs have three isoforms namely PPARα, PPARβ/δ and PPARγ that play a central role in regulating glucose, lipid and cholesterol metabolism where imbalance can lead to obesity, T2DM and CV ailments. It have pathogenic role in diabetes. PPARα is regulates the metabolism of lipids, carbohydrates, and amino acids, activated by ligands such as polyunsaturated fatty acids, and drugs used as Lipid lowering agents. PPAR β/δ could envision as a therapeutic option for the correction of diabetes and a variety of inflammatory conditions. PPARγ is well categorized, an element of the PPARs, also pharmacological effective as an insulin resistance lowering agents, are used as a remedy for insulin resistance integrated with type- 2 diabetes mellitus. There are mechanistic role of PPARα, PPARβ/δ and PPARγ in diabetes mellitus and insulin resistance. From mechanistic way, it revealed that dual PPAR-α/γ agonist play important role in regulating both lipids as well as glycemic levels with essential safety issues.
    [Show full text]
  • Types of Gene Effects Governing the Inheritance of Oleic and Linoleic Acids in Peanut (Arachis Hypogaea L.)
    African Journal of Biotechnology Vol. 11(67), pp. 13147-13152, 21 August, 2012 Available online at http://www.academicjournals.org/AJB DOI:10.5897/AJB12.1498 ISSN 1684-5315 ©2012 Academic Journals Full Length Research Paper Types of gene effects governing the inheritance of oleic and linoleic acids in peanut (Arachis hypogaea L.) Nattawut Singkham1, Sanun Jogloy1*, Bhalang Suriharn1, Thawan Kesmala1, Prasan Swatsitang2, Prasit Jaisil1, Naveen Puppala3 and Aran Patanothai1 1Department of Plant Science and Agricultural Resources, Faculty of Agriculture, Khon Kaen University, Khon Kaen, 40002, Thailand. 2Department of Biochemistry, Faculty of Science, Khon Kaen University, Khon Kaen, 40002, Thailand. 3Agricultural Science Center at Clovis, New Mexico State University, Clovis, New Mexico, 88101, USA. Accepted 3 August, 2012 Oleic and linoleic acids are major fatty acids in peanut determining the quality and shelf-life of peanut products. A better understanding on the inheritance of these characters is an important for high-oleic breeding programs. The objective of this research was to determine the gene actions for oleic acid, linoleic acid, the ratio of oleic to linoleic acids (O/L ratio) and percentage oil (% oil) in peanut. Georgia- 02C, SunOleic 97R (high-oleic genotypes) and KKU 1 (low-oleic genotypes) were used as parents to generate P1, P2, F2, F3, BC11S and BC12S. The entries were planted in a randomized complete block design with four replications in the rainy season (2008) and the dry season (2008/2009). Gas liquid chromatography (GLC) was used to analyze fatty acid compositions. The data were used in generation means analysis to understand gene effects. The differences in season, generation and generation season interactions were significant for oleic acid in the crosses Georgia-02C KKU 1 and SunOleic 97R KKU 1.
    [Show full text]
  • Illuminating Dna Packaging in Sperm Chromatin: How Polycation Lengths, Underprotamination and Disulfide Linkages Alters Dna Condensation and Stability
    University of Kentucky UKnowledge Theses and Dissertations--Chemistry Chemistry 2019 ILLUMINATING DNA PACKAGING IN SPERM CHROMATIN: HOW POLYCATION LENGTHS, UNDERPROTAMINATION AND DISULFIDE LINKAGES ALTERS DNA CONDENSATION AND STABILITY Daniel Kirchhoff University of Kentucky, [email protected] Digital Object Identifier: https://doi.org/10.13023/etd.2019.233 Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Kirchhoff, Daniel, "ILLUMINATING DNA PACKAGING IN SPERM CHROMATIN: HOW POLYCATION LENGTHS, UNDERPROTAMINATION AND DISULFIDE LINKAGES ALTERS DNA CONDENSATION AND STABILITY" (2019). Theses and Dissertations--Chemistry. 112. https://uknowledge.uky.edu/chemistry_etds/112 This Doctoral Dissertation is brought to you for free and open access by the Chemistry at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Chemistry by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known.
    [Show full text]
  • Pdf; Chi 2015 DPP Air in Cars.Pdf; Dodson 2014 DPP Dust CA.Pdf; Kasper-Sonnenberg 2014 Phth Metabolites.Pdf; EU Cosmetics Regs 2009.Pdf
    Bouge, Cathy (ECY) From: Nancy Uding <[email protected]> Sent: Friday, January 13, 2017 10:24 AM To: Steward, Kara (ECY) Cc: Erika Schreder Subject: Comments re. 2016 CSPA Rule Update - DPP Attachments: DPP 131-18-0 exposure.pdf; Chi 2015 DPP air in cars.pdf; Dodson 2014 DPP dust CA.pdf; Kasper-Sonnenberg 2014 phth metabolites.pdf; EU Cosmetics Regs 2009.pdf Please accept these comments from Toxic-Free Future concerning the exposure potential of DPP for consideration during the 2016 CSPA Rule update. Regards, Nancy Uding -- Nancy Uding Grants & Research Specialist Toxic-Free Future 206-632-1545 ext.123 http://toxicfreefuture.org 1 JES-00888; No of Pages 9 JOURNAL OF ENVIRONMENTAL SCIENCES XX (2016) XXX– XXX Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jes Determination of 15 phthalate esters in air by gas-phase and particle-phase simultaneous sampling Chenchen Chi1, Meng Xia1, Chen Zhou1, Xueqing Wang1,2, Mili Weng1,3, Xueyou Shen1,4,⁎ 1. College of Environmental & Resource Sciences, Zhejiang University, Hangzhou 310058, China 2. Zhejiang National Radiation Environmental Technology Co., Ltd., Hangzhou 310011, China 3. School of Environmental and Resource Sciences, Zhejiang Agriculture and Forestry University, Hangzhou 310058, China 4. Zhejiang Provincial Key Laboratory of Organic Pollution Process and Control, Hangzhou 310058, China ARTICLE INFO ABSTRACT Article history: Based on previous research, the sampling and analysis methods for phthalate esters (PAEs) Received 24 December 2015 were improved by increasing the sampling flow of indoor air from 1 to 4 L/min, shortening the Revised 14 January 2016 sampling duration from 8 to 2 hr.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Use of Gamma-Linolenic Acid and Related Compounds for the Manufacture of a Medicament for the Treatment of Endometriosis
    ~" ' MM II II II II I II Ml Ml Ml I II I II J European Patent Office ooo Ats*% n i © Publication number: 0 222 483 B1 Office_„. europeen des brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 18.03.92 © Int. CI.5: A61 K 31/20, A61 K 31/1 6, A61K 31/23 © Application number: 86307533.9 @ Date of filing: 01.10.86 Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of endometriosis. © Priority: 02.10.85 GB 8524276 © Proprietor: EFAMOL HOLDINGS PLC Efamol House Woodbridge Meadows @ Date of publication of application: Guildford Surrey GU1 1BA(GB) 20.05.87 Bulletin 87/21 @ Inventor: Horrobin, David Frederick © Publication of the grant of the patent: c/o Efamol Ltd, Efamol House Woodbridge 18.03.92 Bulletin 92/12 Meadows Guildford, Surrey, GU1 1BA(GB) © Designated Contracting States: Inventor: Casper, Robert AT BE CH DE ES FR GB GR IT LI LU NL SE University Hospital 339 Windermere Road London Ontario N6A 5AS(CA) © References cited: EP-A- 0 003 407 EP-A- 0 115 419 © Representative: Miller, Joseph EP-A- 0 132 089 J. MILLER & CO. Lincoln House 296-302 High EP-A- 0 181 689 Holborn London WC1V 7JH(GB) J. GYNECOL. OBSTET. BIOL. REPROD. vol. 10, no. 5, 1981, pages 465-471 Masson, Paris, FR PH. CALLGARIS et al.: "Endometriose de la paroi abdominale" 00 00 CLINICAL OBSTETRICS AND GYNECOLOGY, 00 vol. 23, no. 3, Sept. 1980, pages 895-900 J.C. WEED: "Prostaglandins as related to en- CM dometriosis" CM CM Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Aloe Ferox 117 Table 9: Phytochemical Constituents of Different Extracts of Aloe CIM- Sheetal Leaves 119
    International Journal of Scientific & Engineering Research ISSN 2229-5518 1 Morphological, in vitro, Biochemical and Genetic Diversity Studies in Aloe species THESIS SUBMITTED TO OSMANIA UNIVERSITY FOR THE AWARD OF DOCTOR OF PHILOSOPHY IN GENETICS IJSER By B. CHANDRA SEKHAR SINGH DEPARTMENT OF GENETICS OSMANIA UNIVERSITY HYDERABAD - 500007, INDIA JULY, 2015 IJSER © 2018 http://www.ijser.org International Journal of Scientific & Engineering Research ISSN 2229-5518 2 DECLARATION The investigation incorporated in the thesis entitled “Morphological, in vitro, Biochemical and Genetic Diversity Studies in Aloe species’’ was carried out by me at the Department of Genetics, Osmania University, Hyderabad, India under the supervision of Prof. Anupalli Roja Rani, Osmania University, Hyderabad, India. I hereby declare that the work is original and no part of the thesis has been submitted for the award of any other degree or diploma prior to this date. IJSER Date: (Bhaludra Chandra Sekhar Singh) IJSER © 2018 http://www.ijser.org International Journal of Scientific & Engineering Research ISSN 2229-5518 3 DEDICATION I dedicateIJSER this work to my beloved and beautiful wife B. Ananda Sekhar IJSER © 2018 http://www.ijser.org International Journal of Scientific & Engineering Research ISSN 2229-5518 4 Acknowledgements This dissertation is an outcome of direct and indirect contribution of many people, which supplemented my own humble efforts. I like this opportunity to mention specifically some of them and extend my gratefulness to other well wisher, known and unknown. I feel extremely privileged to express my veneration for my superviosor Dr. Anupalli Roja Rani, Professor and Head, Department of Genetics, Osmania University, Hyderabad. Her whole- hearted co-operation, inspiration and encouragement rendered throughout made this in carrying out the research and writing of this thesis possible.
    [Show full text]